In gene therapy, CALAA-01 (cyclodextrin-based siRNA nanoparticles, phase I) silenced RRM2 in melanoma with 21% tumor reduction at 0.6 mg/kg, confirming target engagement via RISC loading assays [61]. This evidence concerns the gene RRM2 and neoplasm.